Cadrenal Therapeutics Announces New Chief Medical Officer in Recent SEC Filing

Cadrenal Therapeutics, a biopharmaceutical company listed on the Nasdaq under the ticker symbol CVKD, made a public announcement of leadership changes through an 8-K SEC filing on February 4, 2025. The company detailed the appointment of Dr. James J. Ferguson III as its new Chief Medical Officer. Dr. Ferguson, an esteemed industry expert with over 25 years of experience in cardiovascular healthcare, assumes the role effective immediately.

The Employment Agreement signed on February 4, 2025, outlines Dr. Ferguson’s compensation terms. These include an annual base salary of $505,000, a discretionary annual bonus of up to 40% of the base salary subject to meeting set objectives, and a stock option award for 60,000 shares of the company’s common stock. The stock options will vest in increments with a significant portion vesting over thirty-six months. Dr. Ferguson’s agreement also includes confidentiality provisions and severance details in the case of termination circumstances.

At the age of 71, Dr. Ferguson boasts an impressive career history with significant contributions in the medical field. Before joining Cadrenal, he held notable positions such as Chief Medical Officer at Matinas BioPharma Holdings, Inc., and various roles at Amgen and AstraZeneca. Dr. Ferguson’s vast experience and expertise are expected to propel Cadrenal’s late-stage clinical development efforts, including leading the trials for tecarfarin and spearheading business growth in specialized cardiovascular therapies.

In related news, Cadrenal announced the departure of its former Chief Medical Officer, Dr. Douglas Losordo. The company terminated its employment relationship with Dr. Losordo on amicable terms, with a severance agreement in place. The Severance Agreement, effective February 7, 2025, outlines various compensatory terms for Dr. Losordo, including continued base salary, bonuses, and accelerated vesting of options.

To communicate the recent change in leadership, Cadrenal issued a press release on February 6, 2025. The release underscores the significance of Dr. Ferguson’s appointment in steering the late-stage clinical development of tecarfarin and other related initiatives. Quang X. Pham, CEO of Cadrenal Therapeutics, expressed confidence in Dr. Ferguson’s abilities to drive the company’s clinical development programs effectively.

Cadrenal Therapeutics remains focused on developing specialized cardiovascular therapies, with tecarfarin as a key asset. Tecarfarin, a Vitamin K antagonist, is positioned as a safer alternative to existing treatments for specific cardiovascular conditions. The Company is preparing for a pivotal Phase 3 clinical trial of tecarfarin in LVAD patients and aims to address significant unmet medical needs in this patient population.

This transition in leadership marks a pivotal moment for Cadrenal Therapeutics as it looks towards advancing innovative cardiovascular treatments under the guidance of Dr. James J. Ferguson III.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cadrenal Therapeutics’s 8K filing here.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.